Building a healthier tomorrow
At Intercept, our focus is to develop and deliver novel medicines for those living with rare and serious liver diseases.
Bel, Living with Primary Biliary Cholangitis
Innovating to solve some of today’s toughest medical challenges
Using key discoveries in the field of liver health, we’re advancing treatments for rare and serious liver diseases. Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.
- Continuing to deliver the first and only FDA-approved FXR agonist for the second-line treatment of primary biliary cholangitis (PBC)
- Building on our ongoing commitment to people living with PBC by progressing our research portfolio with a novel fixed-dose combination
- Advancing our pipeline for liver diseases with high unmet need
Aiming to improve lives of people with PBC
Primary biliary cholangitis (PBC) is a rare, progressive, and chronic autoimmune disease that causes bile acid to build up in the liver, resulting in inflammation and scarring (fibrosis), which, if left untreated, can lead to cirrhosis, the need for a liver transplant, or death. Therefore, we believe treatment goals should aim to prevent end-stage liver disease and in turn increase transplant-free survival.
Advancing a pipeline focused on liver diseases with high unmet need
Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.
Ongoing clinical research
Clinical trials are a critical part of developing new medicines.
Biology in pursuit of better health
Farnesoid X Receptor (FXR) biology is at the core of our therapeutic research. This treatment modality has applications for PBC and potentially other liver conditions, such as severe alcohol-associated hepatitis.
About Us
Since 2002, we’ve pioneered a novel scientific platform to answer critical needs in the liver health community and deliver on our mission to build a healthier tomorrow for people with rare and serious liver diseases.
Help us help others
We’re a dynamic, fast-paced biopharmaceutical company driven by purposeful curiosity and a willingness to do things that haven’t been done before. We recognize that developing new treatments is challenging and that it takes commitment, dedication and deep scientific knowledge, but we are inspired by the opportunity to have a meaningful impact on the lives of patients. As a team, we deliver on our commitment through true collaboration and partnership.
Working at Intercept
Our company started as a vision in our founder’s small New York City apartment, and we’ve kept that entrepreneurial spirit as we’ve grown to a commercial-stage company more than 300 people strong with a pipeline of innovative and investigational therapies in development.
Join our team
Our employees are collaborative, passionate and innovative. We embrace our responsibility of pioneering solutions and building hope for patients in need. If you are someone who is self-motivated and sees challenges as opportunities, join us and help us make a difference for those with rare and serious liver diseases.
